Targeting Jun N-terminal kinase phosphorylation: A human-derived hepatoprotective peptide human liver transplantation peptide 1 attenuates hepatic ischemia-reperfusion injury

Figure 4 Human liver transplantation peptide 1 attenuates AML12 cells injury under hypoxia/reoxygenation treatment. A: Cell viability after human liver transplantation peptide 1 treatment; B: Cleaved caspase-3 and Bcl-2 protein expression by western blotting; C: Representative images of terminal deoxynucleotidyl transferase dUTP nick end labeling staining (red) performed on AML12 cells. Nuclei are counterstained with DAPI (blue); D: PCNA protein expression by western blotting; E: Representative immunofluorescence images of AML12 cells stained for the proliferation marker Ki67 (green). Nuclei are counterstained with DAPI (blue). H/R: Hypoxia/reoxygenation; HLTP1: Human liver transplantation peptide 1; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, and ^dP < 0.0001.